Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRLX101 alone or with bevacizumab or mFOLFOX6 in advanced solid tumors
NCT02648711Phase 1Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of CRLX101 in solid tumor (3 arms), sponsored by Lumos Pharma, Inc. Primary endpoint: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 15 months. Started Oct 2015; status: terminated.
02
Drugs
CRLX101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02648711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648711.